Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
PrECOG, LLC.
PrECOG, LLC.
University of Chicago
Mayo Clinic
Peking University First Hospital
Medical College of Wisconsin
University of Kansas Medical Center
M.D. Anderson Cancer Center
Institut Bergonié
Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
Ruijin Hospital
Region Skane
Fundación Sociedad Española de Oncologia Médica
Shanghai Chest Hospital
Turku University Hospital
University of Roma La Sapienza
RenJi Hospital
University of Colorado, Denver
Chinese PLA General Hospital
Bristol-Myers Squibb
Qilu Hospital of Shandong University
Shanghai Chest Hospital
Fujian Medical University Union Hospital
Ruijin Hospital
Mahatma Gandhi Institute of Medical Sciences
Changzhi People's Hospital Affiliated to Changzhi Medical College
Universitaire Ziekenhuizen KU Leuven
Rigshospitalet, Denmark
Persephone Biosciences
Hebei Medical University Fourth Hospital
Huashan Hospital
Vall d'Hebron Institute of Oncology
Shanghai Zhongshan Hospital
National Cancer Institute, Naples